Literature DB >> 32178603

Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme (AESOP) Annual Report 2018.

Geoffrey W Coombs1, Denise A Daley2, Shakeel Mowlaboccus3, Yung Thin Lee3, Stanley Pang1.   

Abstract

From 1 January to 31 December 2018, thirty-six institutions around Australia participated in the Australian Enterococcal Sepsis Outcome Programme (AESOP). The aim of AESOP 2018 was to determine the proportion of enterococcal bacteraemia isolates in Australia that were antimicrobial resistant, and to characterise the molecular epidemiology of the E. faecium isolates. Of the 1,248 unique episodes of bacteraemia investigated, 93.5% were caused by either E. faecalis (54.2%) or E. faecium (39.3%). Ampicillin resistance was not detected in E. faecalis but was detected in 89.4% of E. faecium. Vancomycin non-susceptibility was not detected in E. faecalis but was reported in 45.0% of E. faecium. Overall 49.3% of E. faecium isolates harboured vanA or vanB genes. Of the vanA/vanB positive E. faecium isolates, 52.9% harboured vanA genes and 46.2% vanB genes; 0.8% harboured both vanA and vanB genes. The percentage of E. faecium bacteraemia isolates resistant to vancomycin in Australia is substantially higher than that seen in most European countries. E. faecium consisted of 59 multilocus sequence types (STs) of which 74.4% of isolates were classified into six major STs containing ten or more isolates. All major STs belong to clonal cluster (CC) 17, a major hospital-adapted polyclonal E. faecium cluster. The predominant STs (ST17, ST1424, ST796, ST80, ST1421, and ST262) were found across most regions of Australia. The most predominant clone was ST17 which was identified in all regions except the Australian Capital Territory and the Northern Territory. Overall, 55.8% of isolates belonging to the six predominant STs harboured vanA or vanB genes. The AESOP 2018 study has shown that enterococcal bacteraemias in Australia are frequently caused by polyclonal ampicillin-resistant high-level gentamicin-resistant vanA- or vanB-harbouring E. faecium which have limited treatment options. © Commonwealth of Australia CC BY-NC-ND.

Entities:  

Keywords:  Australian Group on Antimicrobial Resistance; Enterococcus faecalis; Enterococcus faecium; Enterovirus; antimicrobial resistance surveillance; bacteraemia; vancomycin resistant enterococci

Year:  2020        PMID: 32178603     DOI: 10.33321/cdi.2020.44.19

Source DB:  PubMed          Journal:  Commun Dis Intell (2018)        ISSN: 2209-6051


  2 in total

1.  Disease burden, associated mortality and economic impact of antimicrobial resistant infections in Australia.

Authors:  Teresa M Wozniak; Amalie Dyda; Greg Merlo; Lisa Hall
Journal:  Lancet Reg Health West Pac       Date:  2022-07-07

Review 2.  The antimicrobial resistance travel tool, an interactive evidence-based educational tool to limit antimicrobial resistance spread.

Authors:  Fabiana Arieti; Alessia Savoldi; Nithya Babu Rejendran; Marcella Sibani; Maela Tebon; Maria Diletta Pezzani; Anna Gorska; Teresa M Wozniak; Evelina Tacconelli
Journal:  J Travel Med       Date:  2022-07-14       Impact factor: 39.194

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.